BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, April 27, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

med-tech financings
Med-tech financings January 2024

Med-tech financings maintain momentum with $1B raised in January

Feb. 5, 2024
By Amanda Lanier
In the first month of 2024, med-tech financings passed the $1 billion mark once more, raising a total of $1.06 billion through 46 transactions recorded by BioWorld. It was the fourth consecutive month where med-tech financings exceeded the $1 billion threshold, just slightly down from the $1.07 billion raised in December.
Read More

Financings for Feb. 5, 2024

Feb. 5, 2024
Med-tech firms raising money in public or private financings, including: Aclarion, Intelligent Bio Solutions, Procyrion, Vektor Medical.
Read More
Layered  charts

Fractyl prices IPO for type 2 diabetes treatment

Feb. 2, 2024
By Lee Landenberger
The week closed out with two IPOs on their way in. Alto Neuroscience Inc. (NASDAQ:ANRO) and Fractyl Health Inc. (NASDAQ:GUTS) both debuted on Wall Street with offerings looking to raise combined $238.6 million.
Read More
Anbogen

Taiwan’s cancer focused Anbogen raises $12.5M in series A round

Feb. 2, 2024
By Marian (YoonJee) Chu
Taipei-based precision oncology firm Anbogen Therapeutics Inc. drew $12.5 million in a series A funding round to propel two major clinical assets in its cancer pipeline.
Read More

Alto and Fractyl keep the IPO momentum going

Feb. 2, 2024
By Lee Landenberger
The week closed out with two IPOs on their way in. Alto Neuroscience Inc. (NASDAQ:ANRO) and Fractyl Health Inc. (NASDAQ:GUTS) both debuted on Wall Street with offerings looking to raise combined $238.6 million.
Read More
Rare disease illustration

TYRA-300 designated rare pediatric disease drug; Tyra collects $200M

Feb. 2, 2024
By Karen Carey
A rare pediatric disease designation for its achondroplasia treatment and a subsequent $200 million private placement boosted shares of Tyra Biosciences Inc. on Feb. 2 by 29.3%.
Read More

Financings for Feb. 2, 2024

Feb. 2, 2024
Biopharmas raising money in public or private financings, including: Annovis, Biovaxys, Cingulate, Gri, Palatin, Processa, TCG Labs-Soleil, Sunshine, Xortx.
Read More

Financings for Feb. 2, 2024

Feb. 2, 2024
Med-tech firms raising money in public or private financings, including: Avation Medical.
Read More

Financings for Feb. 1, 2024

Feb. 1, 2024
Biopharmas raising money in public or private financings, including: 60 Degrees, Aptose, Basking, Evaxion, Kyverna, Limmatech, Neophore, Panbela, Proniras, Revelation and Revive.
Read More

Financings for Feb. 1, 2024

Feb. 1, 2024
Med-tech firms raising money in public or private financings, including: Alensiaxr, Artera, Novobeing, Synergy Spine.
Read More
Previous 1 2 … 213 214 215 216 217 218 219 220 221 … 667 668 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 24, 2026.
  • Illustration of a tumor

    Detecting the invisible: minimal residual disease at AACR 2026

    BioWorld Science
    Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
  • Boy cupping ear with soundwave graphic

    A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

    BioWorld
    Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
  • Illustration of human face that looks abstract and digital

    AACR 2026: The age of agentic AI in oncology

    BioWorld Science
    New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
  • Chengdu Mfs Pharma synthesizes new compounds for pain

    BioWorld Science
    Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing